Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 severe or critically meta-analysis

HYDRA, 2020
RCThydroxychloroquineplaceboCOVID-19 severe or criticallyNA
75/77 inconclusive
  • inconclusive 1 % decrease in deaths (PE)
RCThydroxychloroquinestandard of careCOVID-19 severe or criticallyNA
61/81 inconclusive
  • inconclusive 4 % increase in deaths (PE)
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.multi-arm study
Mahevas, 2020 OBShydroxychloroquinestandard of careCOVID-19 severe or criticallyserious
84/97 inconclusive
    Yu, 2020 OBShydroxychloroquinecontrolCOVID-19 severe or criticallycritical
    48/520 suggested
    • suggested 68 % decrease in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).